3SBio has posted a net income of $3.94m for the third quarter 2010, or $0.03 per diluted share, compared to net income of $3.35m, or $0.02 per diluted share, for the comparable period in 2009.
Operating income was $4m, compared to $4.18m for the comparable period in 2009.
3SBio has posted a revenue of $35.55m for the nine months ended 30 September 2010, compared to $47.45m for the year ago period.
For the nine months ended 30 September 2010, 3SBio has posted a net income of $10.22m, or $0.07 per diluted share, compared to $11.15m, or $0.07 per diluted share, for the year ago period.
Operating income was $10.91m, compared to $12.39m for the year ago period.
3SBio CEO Jing Lou said that they continue to seek opportunities to introduce products with substantial unmet medical need in the China market.
"Isotechnika’s Voclosporin, a Phase II immunosuppressant is targeted for use in organ transplant therapy," Lou said.
"We are also pleased to announce that EPIAO production has commenced at our new plant in Shenyang which will better enable us to satisfy the growing demand in China as well as explore international biosimilar opportunities."